{"nctId":"NCT00727649","briefTitle":"Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence","startDateStruct":{"date":"2008-07"},"conditions":["Fecal Incontinence"],"count":80,"armGroups":[{"label":"Arm 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Psyllium powder"]},{"label":"Arm 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Loperamide"]}],"interventions":[{"name":"Psyllium powder","otherNames":["Metamucil"]},{"name":"Loperamide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* weekly fecal incontinence\n\nExclusion Criteria:\n\n* fecal impaction\n* inability to complete a baseline 1-week bowel diary\n* rectal prolapse\n* any prior radiation to the pelvis\n* colo-rectal cancer\n* rectal fistula\n* inflammatory bowel disease\n* neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease)\n* constipation (\\<2 bowel movements/week) or total colectomy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"7-day Bowel Diary, Number of Fecal Incontinence Episodes","description":"After consent, 7-day bowel diary was assessed at baseline (2-week visit), during the last week of the 4-week intervention (6-week visit), during the second week of the 2-week wash-out period at 8-weeks, and during the last week of the second 4-week intervention (12 weeks). The mean number of total fecal incontinence episodes from a 7-day bowel diary from each time point was compared between the groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"6.2"},{"groupId":"OG001","value":"7.9","spread":"7.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"4.8"},{"groupId":"OG001","value":"4.1","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"4.2"},{"groupId":"OG001","value":"5.0","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"6.6"},{"groupId":"OG001","value":"4.7","spread":"5.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Bowel Movements With Incontinence","description":"After consent, 7-day bowel diary was assessed at baseline (2-week visit), during the last week of the 4-week intervention (6-week visit), during the second week of the 2-week wash-out period at 8-weeks, and during the last week of the second 4-week intervention (12 weeks). We compared the percentage of the total number of fecal incontinence episodes over the total number of bowel movements from a 7-day bowel diary from each time point between the groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":"18.0"},{"groupId":"OG001","value":"32.3","spread":"23.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":"22.1"},{"groupId":"OG001","value":"21.3","spread":"22.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":"22.2"},{"groupId":"OG001","value":"18.8","spread":"20.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"19.3"},{"groupId":"OG001","value":"18.8","spread":"21.0"}]}]}]},{"type":"SECONDARY","title":"Fecal Incontinence Severity Index Score, FISI","description":"The patient-reported symptoms severity score, the Fecal Incontinence Severity Index (FISI), has 4 questions about the frequency of gas, mucus, liquid stool, and solid stool incontinence. Responses are weighted based on the patient rating of severity and a total score is calculated (range 0-61) with higher scores indicating a greater severity of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":"11.0"},{"groupId":"OG001","value":"31.9","spread":"13.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"12.2"},{"groupId":"OG001","value":"24.9","spread":"13.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":"17.1"},{"groupId":"OG001","value":"23.2","spread":"12.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["excessive flatus","abdominal pain","diarrhea","constipation","bloating"]}}}